All ingredients have been generally recognized as safe or are listed as inactive Ingredients or EAFUS by the USFDA, ANVISA and the Regulation (EC) No 1907/2006 (REACH) when used in accordance with their intended purposes.

About Fagron

Fagron’s strategy is focused on the optimization and innovation of pharmaceutical compounding. As an R&D scientific pharmaceutical compounding supplier, Fagron wants to widen the therapeutic scope of the prescriber to enable tailor-made pharmaceutical care. Through its activities, Fagron supports the unique selling point of the pharmacist.

Newsletter

Sign up to receive our bimonthly e-newsletter with the latest Fagron innovations and compounding news.